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The advent of targeted therapy presents an unprecedented opportunity for advances in the treatment of cancer. A key challenge will
be to translate the undoubted promise of targeted agents into tangible clinical benefits. Achieving this goal is likely to be dependent
upon a number of factors. These include continued research to improve our understanding of the heterogeneity and complexity of
the tumour microenvironment; refinement of clinical trial design to incorporate nontraditional end points such as the optimum
biological dose and health-related quality of life; and the use of technological advancements in proteomics, genomics and biomarker
development to better predict tumour types and patient subsets that may be particularly responsive to treatment, as well as enable a
more accurate assessment of drug effect at the molecular level. In summary, the future success of targeted agents will require an
integrated multidisciplinary approach involving all stakeholders.
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The development of targeted agents holds considerable promise
for cancer treatment but progress to date has not been easy.
Many of the difficulties encountered in the development of
targeted anticancer agents can be explained by an incomplete
understanding of human tumour biology, limited understanding
of the drug target and problems with patient selection. The
development of targeted anticancer agents has required novel trial
designs as well as the investigation of new pharmacodynamic and
surrogate trial end points. The future success of targeted therapy
will involve initiatives to identify the most promising targets,
closer integration of preclinical and clinical data, a greater use of
genomic and proteomic techniques, and further refinement of trial
design.
SELECTING TARGETED AGENTS FOR TARGETED
PATIENT POPULATIONS
Most cancers are driven by and dependent upon multiple aberrant
signalling pathways, and thus ‘single-hit’ therapy may not
represent an optimal approach in many clinical situations. It is
evident that there is scope for significant redundancy in cell
signalling and selecting a single target within a heterogeneous
tumour type may yield clinically disappointing results. In tumours
with a relatively narrow range of critical genetic defects (e.g., acute
promyelocytic leukaemia and chronic phase chronic myeloid
leukaemia (CML)), the ability to develop successful targeted agents
with striking activity has been more easily accomplished than in
more complex and heterogeneous tumour types (e.g., breast
cancer, and non-small-cell lung cancer (NSCLC)). Most clinically
apparent tumours contain multiple genetic defects with incomple-
tely defined phenotypic consequences. The declining therapeutic
impact of imatinib as one proceeds in Philadelphia-positive CML
from chronic-phase disease to accelerated phase, and finally to
blast crisis, illustrates the impact of increasing genetic alterations
in conferring drug resistance to a targeted agent (Gorre et al, 2001;
von Bubnoff et al, 2002). For successful targeted drug development
we ideally need to be able to identify targets that provide a critical
transforming signal to the tumour as distinct from targets where
expression is not linked with signal-dependency. We must also
acknowledge that targeted drugs may have the most marked effects
on only a subset of tumour cells and may be incapable of inhibiting
quiescent and perhaps non-‘target-addicted’ tumour stem cell
populations. Targeted drugs may therefore be able to provide
tumour control rather than cure.
The clinical evaluation of targeted agents has provided some
refinement in the classification of complex tumours, and this trend
is likely to gather pace as tumours become defined by molecular
features rather than according to light microscopic classification.
The emergence of trastuzumab as a useful agent in a subset of
breast cancer patients is one example of the impact of targeted
treatment in refining tumour classification (Vogel et al, 2002).
Likewise, the finding that a small subset of NSCLC patients who
have gain-of-function epidermal growth factor receptor (EGFR)
mutations and response rates to gefitinib and erlotinib of over
80% must be viewed as a major advance in our understanding of
lung cancer biology (Lynch et al, 2004; Paez et al, 2004; Mitsudomi
et al, 2005; Tokumo et al, 2005). The future clinical evaluation
of targeted agents will shed new light on tumour pathogenesis,
provide better understanding of tumour biology and result in
changes to the way that tumours are classified.
For trastuzumab (Herceptin
s) and imatinib (Glivec
s), a limited
number of molecular features can be used to define a suitable
target patient population, but it seems unlikely that all patients
who could derive clinical benefit from targeted drugs will be
identified by determination of a single molecular feature. We know
also that tumour architecture is heterogeneous and may signifi-
cantly affect the intratumoural pharmacokinetics of a drug (Jayson
et al, 2002). Thus, a drug that is effective at the molecular level may
not necessarily achieve clinically useful doses in the tumour. *Correspondence: Dr M Ranson; E-mail: malcolm.ranson@man.ac.uk
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multiple-targeted agents or to drugs that target generic, funda-
mental tumour processes such as angiogenesis, apoptosis and
cellular proliferation. For example, small molecule tyrosine kinase
inhibitors (TKIs) such as ZD6474 (inhibitor of vascular endothelial
growth factor receptor (VEGFR) and EGFR) (Wedge et al, 2002;
Ciardiello et al, 2003), SU11248 (inhibitor of VEGFR, platelet-
derived growth factor receptor (PDGFR), c-Kit, colony-stimulating
factor receptor-1 (CSFR-1) and FLT3-R) and vatalanib (PTK787/
ZK222584; inhibitor of VEGFR and PDGFR) (Abrams et al, 2003;
Thomas et al, 2003) show activity against more than one receptor
and are inhibitory in a wide range of preclinical models.
Since there are no predefined predictive rules, a major future
challenge must be to identify critical molecular events that drive
tumour growth, survival and metastasis. Important determinants
of tumour behaviour are likely to be DNA mutational or
rearrangement events, which produce oncogenes with dominant
gain of function or tumour suppressor genes with recessive loss of
function.
CLINICAL TRIAL DESIGN
The traditional phase I trial design used for cytotoxic drugs has
been recognised as having limitations for targeted agents. Instead
of the maximum tolerated dose, definition of the optimum
biological dose became a central theme in phase I studies (Gelmon
et al, 1999; Korn et al, 2001). However, a retrospective review of
60 phase I trials of targeted agents reported mainly between 1999
and 2002 revealed that the majority of studies had used toxicity as
the sole determinant for dose selection in phase II studies.
Nontraditional end points such as measurements of drug effect or
functional imaging have not been routinely incorporated into
phase I trial design and have rarely formed the basis for future
dose selection or trial design (Parulekar and Eisenhauer, 2004).
Proof-of-principle studies to measure drug effect on target are
highly desirable during early drug development, but are difficult
to perform. Although tumour represents the tissue of primary
interest, tumour sampling can be obtained in only a limited
proportion of patients and at a small number of time points. Trials
with mandatory biopsies have greater ethical and administrative
complexity and the net result is often slower patient recruitment
and recruitment of a narrow range of tumour types. Preclinical
models are needed that define an appropriate degree of target
inhibition for clinical studies, but observations of target inhibition
still need to be clinically validated. Surrogate tissues (peripheral
blood mononuclear cells, skin, hair follicles) may be useful in that
they can be more readily collected than tumour biopsies, but the
pharmacodynamic relationship between surrogate and tumour
cells needs to be understood and defined. The incorporation of
surrogate and tumour pharmacodynamic markers into clinical
trials has also highlighted the fact that assay validation, reliability
and quality assurance need attention if results are to be
interpretable (Colburn, 2003; Cummings et al, 2004).
Once an agent has been found to have acceptable toxicity in
phase I (ideally with proof-of-principle that it has achieved
inhibition of the putative biological target), it is necessary to
demonstrate that it has clinical activity in phase II and III trials.
Patient selection for such trials is often problematic, particularly
if there is no established link between the chosen target and a
‘diagnostic signature’. Translational research has established a
significant correlation between genomic amplification and high
expression of HER2/neu in advanced breast cancer, and response
and clinical benefit from trastuzumab (Vogel et al, 2002). However,
the predictive capacity of this observation has its limitations, since
despite the development of validated molecular diagnostics for
HER2, only a minority of patients with HER2/neu-positive
tumours will actually respond to trastuzumab monotherapy.
However, the relatively high response rates in phase II/III trials
of imatinib in metastatic gastrointestinal stromal tumours (GIST)
support the intrinsic power of a science-driven approach to patient
selection (van Oosterom et al, 2001; Demetri et al, 2002). Imatinib
is an inhibitor of c-Kit receptor tyrosine kinase, and constitutive
activation of this receptor, resulting from gain-of-function
mutations in the c-Kit gene, had been hypothesised to be critical
in GIST (Rubin et al, 2001). The situation for EGFR TKIs has
however been more challenging. In this case, the target receptor
was found to be widely expressed in epithelial tumours and strong
preclinical data supported a role for EGFR in epithelial tumour
biology. Nevertheless, the relationship between EGFR expression,
target inhibition and tumour dependency on EGFR was unclear,
and it was clinical observations that propelled a breakthrough in
basic science. Responses to gefitinib in advanced NSCLC were
encountered in a minority of patients who more frequently had
adenocarcinoma, were non- or ex-smokers, and were more likely
to be female or Japanese (Fukuoka et al, 2003; Kaneda et al, 2004;
Miller et al, 2004). Molecular characterisation of responding
patients identified a novel subset of NSCLC patients with gain-of-
function mutations in the ATP-binding domain of the receptor
(Lynch et al, 2004; Paez et al, 2004; Mitsudomi et al, 2005; Tokumo
et al, 2005). Had this biology been known in advance, patient
selection based upon this criterion could have yielded a response
rate to gefitinib and erlotinib of over 80% in phase II trials in
this subset of NSCLC. Analysis of randomised clinical data with
erlotinib suggests that this select cohort of mutation-positive
patients does not fully explain the survival differences between
erlotinib and best supportive care in relapsed NSCLC (Shepherd
et al, 2004), and it is sobering to reflect that this observation would
be precluded by ‘a priori’ selection of patients based on EGFR
mutation status. Similarly, the careful evaluation of imatinib-
resistant patients has fuelled new understanding of CML biology
and facilitated the development of second-generation lead
compounds (Ross and Hughes, 2004). While there is an over-
whelming case for strong science-driven trials, the ability of trials
to drive basic science should not be underestimated.
It is unlikely that all patients who will experience clinical benefit
will be identified by ‘single gene’ analysis or a single molecular
marker because of the complexity of most tumour phenotypes.
Genomic and proteomic profiling to examine a larger number of
genes and proteins can elucidate more complex molecular
signatures, and a number of such profiles have been defined,
which predict survival or treatment response (Van’t Veer et al,
2003; Yanagisawa et al, 2003; Carr et al, 2004). These technologies
can also be applied to targeted therapies, although greater efforts,
including some degree of speculative translational research on
clinical samples, will be required to develop this area rapidly.
The choice of response rate as a primary clinical end point in
phase II trials of targeted drugs needs to be questioned. Tumour
regression has remained the benchmark against which drugs are
normally assessed in phase II despite the fact that time to
progression may be a more relevant phase II end point for many
targeted agents. In addition, some of these novel agents may take
longer to stabilise disease than traditional cytotoxic agents, and we
may need to use less stringent definitions of progressive disease so
that patients can be exposed to an experimental drug for longer.
IDENTIFYING AND VALIDATING MARKERS OF
TARGET INHIBITION
Although most phase I trials of targeted drugs incorporate
translational science, the same cannot be said of many phase II
or III trials despite the fact that this arena is likely to be one of the
most fruitful for translational science. The ability to perform
analysis at DNA, RNA and protein levels and to correlate this with
outcome in phase II and III trials should facilitate our ability to
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gain from targeted therapeutics. In practice, most patients are
willing to have additional investigative studies performed on their
tumours in the hope that it may yield important information. It is
important that all stakeholders involved in the clinical testing of
new anticancer agents understand that the correlation of such data
with clinical outcome may be critical for the optimal development
and use of current and future targeted therapies. Thus, incorpor-
ating translational research into phase II and III trials needs to be
recognised as an important future objective.
Dose delivery with cytotoxic drugs is normally heavily
influenced by normal tissue toxicity (e.g., myelosuppression and
mucositis). It seems a reasonable premise that dosing for targeted
therapies should be driven by target effect rather than toxicity.
While this does not remove the need to evaluate traditional clinical
end points (toxicity, tumour response, time to progression and
survival), there is increasing interest in identifying biomarkers of
drug effect. With the relatively low toxicity of many targeted agents
compared with conventional treatment strategies, the short-term
administration of a targeted agent before elective surgery may be
a useful method for identifying biomarkers that merit further
clinical investigation.
CONCLUSION
There are unprecedented opportunities to translate our under-
standing of tumour biology into more significant therapeutic
gains. However, we must accept that our understanding of clinical
human cancer is incomplete and that there are many obstacles to
overcome. Identifying a molecular target that can be inhibited and
then simply testing a promising lead compound in unselected
patients may not be an effective strategy without determining
target effect or conducting adequate translational research. As the
numbers of patients treated with targeted agents increases, it will
become possible to determine whether significant tumour
dependency exists for a specific biological target, at least in a
subset of patients. Indeed, phase III trials of bevacizumab have
recently validated VEGF as a target in both CRC (Hurwitz et al,
2004). We should attempt to elucidate potential mechanisms
whereby tumours circumvent this target dependency, as this may
help us in patient selection and finding effective combination
therapies. Initial clinical development should focus on proof-of-
principle, a demonstration that the drug produces inhibition of the
biological target at doses that are well tolerated, and that the
consequences of target inhibition can be identified and measured
using validated surrogates for clinical benefit. This will require the
integration of pharmacokinetics, pharmacodynamics and possibly
functional imaging into trials. Selection of a specific population of
patients is desirable if adequate clinical or preclinical data exists.
In the absence of data allowing patient enrichment, further
preclinical work may be required or significant investment in
gathering tumour and correlative material should be undertaken in
phase I and II studies. Technologies such as genomics, proteomics
and biomarker development represent promising approaches with
which to probe for predictive markers. Everyone involved in
developing novel targeted anticancer therapies should recognise
that the most significant future advances are likely to emerge from
the incorporation of such technologies into clinical trials. In short,
the future success of targeted therapies will need a coordinated,
multidisciplinary team approach.
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